Journal
NATURE REVIEWS MATERIALS
Volume 6, Issue 2, Pages 103-106Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41578-020-00277-6
Keywords
-
Funding
- Mayo Clinic Center for Regenerative Medicine in Florida
- National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), United States [R21AI152318, R01AI144997]
- NIH Common Fund through the Office of Strategic Coordination/Office of the NIH [UG3CA241694]
Ask authors/readers for more resources
Cell-released biological nanoparticles, known as extracellular vesicles (EVs), are emerging drug carriers with high complexity. EV-based drug delivery leverages intrinsic mechanisms for molecular transport in the body, and integrating EV biology and manufacturing with clinical insights from synthetic nanoparticles is likely to significantly advance the field of drug delivery.
Cell-released biological nanoparticles, that is, extracellular vesicles (EVs), are emerging drug carriers with high complexity. EV-based drug delivery exploits intrinsic mechanisms for molecular transport in the body. Integrating EV biology and manufacturing with clinical insights from synthetic nanoparticles is likely to substantially advance the field of drug delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
